A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

In March 2014, Regeneron filed a patent infringement suit in the Southern District of New York against Dutch biotech firm Merus (NASDAQ:MRUS) to remedy Merus’ infringement of the ‘018 patent ...

In one example of a lucrative patent thicket, AbbVie notoriously gained more than 100 patents on its megablockbuster Humira. Despite complaints, a court found the strategy legal .

Regeneron has a very strong pipeline ... EYLEA revenue after patent expiration. Regeneron has been generating an impressive amount of ... its immuno-oncology development strategy.

Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court.

Oct 4 - Biotech company Regeneron Pharmaceuticals (REGN.O), opens new tab lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 ...

Amgen 's ( AMGN) patents covering LDL cholesterol-lowering drug Repatha are likely to be invalidated in the wake of a court battle with Regeneron Pharmaceuticals ( REGN) and Sanofi ( SNY), an ...

As we have previously reported, Regeneron’s BPCIA case against Mylan regarding Mylan’s proposed aflibercept biosimilar is proceeding on an expedited schedule, with a two-week trial scheduled ...

ERS Genomics holds rights to foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology. "We are pleased to include Regeneron, a ...

Chalk one up for antibody maker Kymab. The U.K. Supreme Court invalidated a pair of Regeneron patents around antibody-producing mice, putting to rest a lawsuit Regeneron filed against Kymab seven ...